Talphera (TLPH) Preferred Stock Liabilities (2010 - 2022)
Talphera (TLPH) posted Preferred Stock Liabilities of $315000.0 for Q3 2022, down 99.44% on a QoQ basis from $55.9 million in Q4 2010.
Powered by 
Analysis
Talphera (TLPH) Preferred Stock Liabilities (2010 - 2022) Analysis & Trends
Talphera has reported Preferred Stock Liabilities for 2 years, with the latest figure at $315000.0 in Q3 2022.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $315000.0 in Q3 2022; TTM through Sep 2022 was $315000.0, a N/A change from a year earlier, with the FY2010 full-year figure at $55.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $315000.0 for Q3 2022 at Talphera, down from $55.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $315000.0 in Q3 2022, with the low at $315000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | - |